                         SEQUENCE LISTING

<110>  BioNTech Cell & Gene Therapies GmbH
 
<120>  AGENTS AND METHODS FOR ACTIVATION AND TARGETING OF IMMUNE 
       EFFECTOR CELLS

<130>  674-381 PCT2

<150>  PCT/EP2021/065290
<151>  2021-06-08

<160>  9     

<170>  PatentIn version 3.5

<210>  1
<211>  47
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  5'-UTR

<400>  1
aacuaguauu cuucuggucc ccacagacuc agagagaacc cgccacc                     47


<210>  2
<211>  311
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  3'-UTR

<400>  2
cucgagagcu cgcuuucuug cuguccaauu ucuauuaaag guuccuuugu ucccuaaguc       60

caacuacuaa acugggggau auuaugaagg gccuugagca ucuggauucu gccuaauaaa      120

aaacauuuau uuucauugcu gcgucgagag cucgcuuucu ugcuguccaa uuucuauuaa      180

agguuccuuu guucccuaag uccaacuacu aaacuggggg auauuaugaa gggccuugag      240

caucuggauu cugccuaaua aaaaacauuu auuuucauug cugcgucgag accuggucca      300

gagucgcuag c                                                           311


<210>  3
<211>  278
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  3'-UTR

<400>  3
cugguacugc augcacgcaa ugcuagcugc cccuuucccg uccuggguac cccgagucuc       60

ccccgaccuc gggucccagg uaugcuccca ccuccaccug ccccacucac caccucugcu      120

aguuccagac accucccaag cacgcagcaa ugcagcucaa aacgcuuagc cuagccacac      180

ccccacggga aacagcagug auuaaccuuu agcaauaaac gaaaguuuaa cuaagcuaua      240

cuaaccccag gguuggucaa uuucgugcca gccacacc                              278


<210>  4
<211>  110
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  A30L70

<400>  4
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa gcauaugacu aaaaaaaaaa aaaaaaaaaa       60

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa                 110


<210>  5
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Epitope tag

<400>  5

Ser Arg Leu Glu Glu Glu Leu Arg Arg Arg Leu Thr Glu 
1               5                   10              


<210>  6
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1

<400>  6

Gly Val Thr Ile Ser Ala Leu Asn Ala Met Ala Met Gly 
1               5                   10              


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2

<400>  7

Ala Val Ser Glu Arg Gly Asn Ala Met 
1               5                   


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3

<400>  8

Leu Glu Asp Arg Val Asp Ser Phe His Asp Tyr 
1               5                   10      


<210>  9
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VHH

<400>  9

Glu Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Val Thr Ile Ser Ala Leu 
            20                  25                  30          


Asn Ala Met Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Glu Arg Arg 
        35                  40                  45              


Val Met Val Ala Ala Val Ser Glu Arg Gly Asn Ala Met Tyr Arg Glu 
    50                  55                  60                  


Ser Val Gln Gly Arg Phe Thr Val Thr Arg Asp Phe Thr Asn Lys Met 
65                  70                  75                  80  


Val Ser Leu Gln Met Asp Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys His Val Leu Glu Asp Arg Val Asp Ser Phe His Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Gln Val Thr Val Ser Ser 
        115                 120         


